The Top 50 Big Pharma Partnering and M&A Deal Trends
report provides comprehensive and in-depth insight into the dealmaking
interests and activity of the worlds leading fifty big pharma companies.
Description
The Top 50 Big Pharma Partnering and M&A Deal Trends
report provides the most comprehensive and in-depth insight into the dealmaking
interests and activity of the worlds leading fifty big pharma companies.
The Partnering Deals and Alliances with Big Pharma report
provides the most comprehensive and in-depth insight into the dealmaking interests
and activity of the worlds leading fifty big pharma companies.
This premier report provides all the information you
require to better understand big pharma partnering.
One of the key aspects of partnering is finding those
companies that are potential candidates for the development and
commercialization of the next generation of therapies. A lot of resources are
spent on finding partners, identifying their interests and making contact to
initiate discussions.
Using this report, dealmakers will effectively and
efficiently target their partnering activities to deliver the company’s
business development objectives. Over 300 charts allow quick understanding of
each big pharma companies dealmaking trends over the last four years.
This report contains over 3,000 links to online copies of
actual partnering deals as recorded at Current Agreement, together with
contract documents if submitted to the Securities Exchange Commission by
bigpharma and their partners.
Contract documents provide the answers to numerous
questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.
The initial chapters of this report provide an
orientation of big pharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst
chapter 2 lists the top 50 leading big pharma companies based on 2013
pharmaceutical revenues and dealmaking activity since 2009.
Chapter 3 reviews the top partnering and M&A deals of
2009-2014 according to reported deal size.
Chapter 4 provides a summary on best practice on how to
submit an opportunity to big pharma, to ensure building of relationships and to
obtain a prompt assessment and response from the business development function
of the prospective partner.
Chapter 5 lists forthcoming partnering events where
valuable face to face meetings with big pharma provide a highly effective means
of obtaining interest in novel opportunities. These events are where dealmaking
gets initiated through numerous back to back meetings.
The main body of the report is provided in chapter 6.
In-depth profiles of every big pharma company provide everything required to
assess the suitability of a company as a prospective partner. Each profile
includes a company overview, partnering activity according to deal type, phase
of development, therapy area and technology type.
Each company profile provides a comprehensive listing of
deal records available at Current Agreements, each of which links direct to an
online copy of the actual deal record plus contract document if filed with the
SEC.
One of the key aspects of partnering is conducting due
diligence on a partner to determine under what terms a prospective partner
agrees to a partnering relationship.
Understanding the flexibility of a prospective partners’
negotiated deals terms provides critical insight into the negotiation process
in terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments clauses,
the devil is in the detail in terms of how payments are triggered – contract
documents provide this insight where press releases and databases do not.
This data driven report contains over 3,000 links to
online copies of actual deal records at Current Agreements and contract
documents, where submitted to the Securities Exchange Commission by companies
and their partners. Contract documents provide the answers to numerous
questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.
In addition, contract documents provide the answers to numerous
questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.
In summary, the report provides the reader with the tools
necessary to make successful contact with the right big pharma partners
effectively and efficiently.
Benefits
Top 50 Big Pharma Partnering and M&A Deal Trends
provides the user with the following key benefits:
- Detailed partnering activity profiles for each of the top 50 big pharma companies
- Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
- Partnering therapy focus revealed
- Partnering activity since 2009 – number of deals per year
- Full listing of partnering deals
- Activity by deal type
- Activity by industry sector
- Activity by phase of development
- Activity by technology type
- Activity by therapeutic area
- Comprehensive access to over 3,000 partnering deals, together with contract documents if available
- Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 816 pages, “Top 50 Big Pharma Partnering and M&A Deal Trends” report
covering the Introduction, Big pharma top 50 dealmaking activity, Top big
pharma deals by value, Submitting Opportunities to Big Pharma, Forthcoming big
pharma partnering events, Big pharma Company Profiles, Resources, Appendices.
Know
more about this report at – http://mrr.cm/ZDN
Find
all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.